Literature DB >> 7829210

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

A Guha1, K Dashner, P M Black, J A Wagner, C D Stiles.   

Abstract

Established cell lines derived from human malignant astrocytomas typically express a combination of platelet-derived growth factor (PDGF) and PDGF receptor which could form an autocrine loop. In this study, we screened for the essential components of a PDGF autocrine loop in fresh surgical isolates of human astrocytomas, using in situ hybridization and immunohistochemical techniques. Eight malignant astrocytomas (6 glioblastomas and 2 anaplastic astrocytomas), 5 low-grade astrocytomas and 4 non-neoplastic glial specimens (mesial temporal sclerosis) were evaluated. Malignant astrocytomas, and to a lesser extent low-grade astrocytomas, expressed more PDGF-A and PDGF-B than non-neoplastic glia. PDGF-alpha-receptor expression was elevated both in malignant and in low-grade astrocytomas. These data support the argument that PDGF autocrine loops contribute to the unregulated growth of human astrocytomas. Expression of PDGF and PDGF receptor in low-grade astrocytomas suggests that activation of PDGF autocrine loops may be an early event in the pathogenesis of malignant astrocytomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829210     DOI: 10.1002/ijc.2910600206

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  70 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Authors:  Ai-Hua Gong; Ping Wei; Sicong Zhang; Jun Yao; Ying Yuan; Ai-Dong Zhou; Frederick F Lang; Amy B Heimberger; Ganesh Rao; Suyun Huang
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

3.  Reinduction of ErbB2 in astrocytes promotes radial glial progenitor identity in adult cerebral cortex.

Authors:  H T Ghashghaei; Jill M Weimer; Ralf S Schmid; Yukako Yokota; Ken D McCarthy; Brian Popko; E S Anton
Journal:  Genes Dev       Date:  2007-12-15       Impact factor: 11.361

Review 4.  PDGF/PDGFR axis in the neural systems.

Authors:  Susmita Sil; Palsamy Periyasamy; Annadurai Thangaraj; Ernest T Chivero; Shilpa Buch
Journal:  Mol Aspects Med       Date:  2018-02-06

Review 5.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

6.  Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells.

Authors:  Wiltrud Lederle; Hans-Jürgen Stark; Mihaela Skobe; Norbert E Fusenig; Margareta M Mueller
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

9.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Michael J Fisher; Sarah S Milla; Kenneth J Cohen; Jeffrey H Wisoff; David H Harter; Judith D Goldberg; Tsivia Hochman; Amanda Merkelson; Michael C Bloom; Angela J Sievert; Adam C Resnick; Girish Dhall; David T W Jones; Andrey Korshunov; Stefan M Pfister; Charles G Eberhart; David Zagzag; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2014-05-06       Impact factor: 12.300

10.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Authors:  Eric Raymond; Alba A Brandes; Christian Dittrich; Pierre Fumoleau; Bruno Coudert; Paul M J Clement; Marc Frenay; Roy Rampling; Roger Stupp; Johan M Kros; Michael C Heinrich; Thierry Gorlia; Denis Lacombe; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.